The study demonstrated that PLE effectively prevented HFD-induced hepatic steatosis in ApoE−/− mice and suggested that PLE treatment could protect against MAFLD by improving the intestinal barrier function and reducing the LPS levels and liver TLR4/MyD88-mediated inflammation in HFD-induced ApoE−/− mice. This evidence concerns the gene TLR4 and fatty liver disease.